Thursday, December 10, 2020

Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: A meta-analysis

So nothing for cognitive impairment. I guess your doctors can't translate research into action even before stuff is clinically proven? 

Did your doctor and stroke hospital do one damn thing with all this earlier research? I'd suggest mass firings.

Growth Hormone Improves Cognitive Function After Experimental Stroke

April 2018

Growth Hormone (GH) Administration Increases the Metabolic Activity of the left Hippocampus in an Elder Patient with Cognitive Disorders

May 2018

Growth hormone could play critical role in stroke rehabilitation and recovery, Hunter researchers say

 

May 2018

Brain fertiliser nurtures new hope for stroke survivors

September 2018

11 Ways to Boost Human Growth Hormone (HGH) Naturally

September 2018 

This is your doctor's responsibility, don't let her/him wash their hands of it and ignore the problem they caused by doing nothing to stop the 5 causes of the neuronal cascade of death in the first week. 

The latest here:

Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: A meta-analysis

 


  • Jin Ok Kim, 
  • Soo Joo Lee, 
  • Jung-Soo Pyo
PLOS
x

Abstract

Cognitive impairment is a common complication observed after a stroke. Currently there are no definitively proven pharmacologic therapies for recovery from post-stroke cognitive impairment and vascular dementia. In this meta-analysis, we evaluated the efficacy and safety of cholinesterase inhibitors in their improvement of cognition in patients with post-stroke cognitive impairment and vascular dementia. We conducted a meta-analysis using seven eligible studies from 305 published articles. We investigated the differences in Mini–Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores, before and after cholinergic augmentation in patients with post-stroke cognitive impairment and vascular dementia. MMSE and ADAS-cog scores were also compared during the subsequent follow-up periods. MMSE score of patients with post-stroke cognitive impairment was increased after cholinergic augmentation throughout the 24 weeks with mean differences [MD] of 3.000, 1.732, 1.578 1.516, and 1.222, at 4, 4–8, 8–12, 12–18, and 18–24 weeks, respectively. In addition, ADAS-cog scores decreased at 6, 12, 18, and 24 weeks by pharmaceutical augmentation, but not with placebo with mean differences [MD] of -2.333, -2.913, -2.767, -2.416, and -1.859, respectively. This meta-analysis shows that acetylcholinesterase inhibitors maintain a stable pattern of improved cognitive function in patients with post stroke cognitive impairment and vascular dementia without the increased risk of side effects.

No comments:

Post a Comment